Neuron– tag –
-
Liv Hospital Accelerates iPSC Therapy with Bioreactor Investment, Targeting Parkinson’s Disease
Liv Hospital Turkey Overview Liv Hospital is addressing the critical challenge of safe and efficient mass production of induced pluripotent stem cells (iPSCs) through a major investment in advanced bioreactor systems. This initiative aim... -
XellSmart Secures FDA Fast Track Designation for Off-the-Shelf iPSC-Derived Cell Therapy XS411 for Parkinson’s Disease
BioSpace (XellSmart) USA Overview XellSmart announced that its allogeneic, off-the-shelf iPSC-derived cell therapy candidate, XS411, for Parkinson's disease has received Fast Track Designation (FTD) from the U.S. FDA. XS411 aims to repla... -
Novo Nordisk Confirms 12-Month Safety and Feasibility of ESC-Derived Dopaminergic Cell Therapy for Parkinson’s in Phase 1/2 Trial
Regen Report USA Overview Novo Nordisk has announced positive 12-month safety and feasibility data from its Phase 1/2 clinical trial of embryonic stem cell (ESC)-derived dopaminergic cells for Parkinson's disease, published in Nature Med... -
Phase 1/2a Trial of Autologous iPSC-Derived Dopaminergic Progenitors for Parkinson’s Shows Positive 12-Month Interim Results in 8 Patients, Demonstrating Favorable Safety and Functional Improvement
International Society for Stem Cell Research USA Overview Interim clinical results from the first Phase 1/2a trial of autologous iPSC-derived dopaminergic progenitor cells for Parkinson's Disease were presented at ISSCR 2026, showing fav... -
EU Approves Itvisma: Single-Dose Gene Therapy Redefines SMA Treatment for Broad Patient Population Aged 2+
BioSpace (via Novartis press release) Europe Overview Novartis' gene therapy Itvisma® (onasemnogene abeparvovec) has received European Commission approval for children, adolescents, and adults aged 2 years and older with 5q spinal muscul... -
Australian iCamuno Biotherapeutics Launches Clinical Trial for Parkinson’s with ‘Hypoimmune Neural Cell Therapy’ Avoiding Immunosuppression
News Hub (Australia) Australia Overview Supported by A$4.6 million from the Australian government's Medical Research Future Fund, iCamuno Biotherapeutics has initiated a five-year research program to evaluate a novel stem cell therapy fo... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
Amerigo Scientific Unveils Advanced iPSC-Derived Cells to Propel Biomedical Research and Cell Therapy
24-7PressRelease.com (Amerigo Scientific発表) USA Overview Amerigo Scientific has launched a new portfolio of high-purity, iPSC-derived cells, including advanced reporter lines, aimed at accelerating biomedical research and cell therapy ... -
iPS-Derived Dopaminergic Neuron Transplants Show Early Safety and Efficacy, Offering New Hope for Parkinson’s Disease Treatment
NeurologyLive USA Overview Stem cell therapy involving the transplantation of iPS cell-derived dopaminergic neurons into the brain is emerging as a promising approach for Parkinson's disease (PD) treatment. Initial clinical trial results... -
Stem Cell Therapies for Parkinson’s Disease Advance to Clinical Stages: BlueRock’s Phase 3 and Japanese iPSC Program Lead the Way
NeurologyLive USA Overview Stem cell therapies for Parkinson's Disease, particularly dopamine cell replacement trials, are making significant strides into advanced clinical stages. BlueRock Therapeutics' embryonic stem cell (ESC)-derived...
